Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy and safety of the test formulation of
Naftifine HCl Cream 1% (Taro Pharmaceuticals Inc.) as compared to the already marketed
formulation Naftin® (Naftifine HCl) 1% Cream (Merz Pharmaceuticals) and placebo in patients
with tinea pedis and to show the superiority of the active treatments over placebo when dosed
once a day for 28 days.